Sunitinib Impurities

Show
per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
N-(2-aminoethyl)-N-ethylnitrous amide Sunitinib

N-(2-aminoethyl)-N-ethylnitrous amide

VE0010008 N/A
N-Desethyl Sunitinib Sunitinib

N-Desethyl Sunitinib

VE0014591 356068-97-8
N-Nitroso Sunitinib Sunitinib

N-Nitroso Sunitinib

VE0015661 N/A
Sunitinib Amide Impurity Sunitinib

Sunitinib Amide Impurity

VE0018299 1186651-51-3
Sunitinib Dimethyl Amide Analog Sunitinib

Sunitinib Dimethyl Amide Analog

VE0017721 1348032-93-8
Sunitinib Impurity 35 Sunitinib

Sunitinib Impurity 35

VE0020048 56341-41-4
Sunitinib Impurity 44 Sunitinib

Sunitinib Impurity 44

VE0017636 1104253-05-5
Sunitinib Impurity 8 Sunitinib

Sunitinib Impurity 8

VE0017627 N/A
Sunitinib N-Oxide impurity Sunitinib

Sunitinib N-Oxide impurity

VL4380001 356068-99-0
Sunitinib-D10 Sunitinib

Sunitinib-D10

DVE001220 1126721-82-1

Vancomycin Related Compound

Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat to the stomach) in patients whose tumors were not successfully treated with imatinib (Gleevec) or who are unable to take imatinib.

References

  • “Sunitinib: Uses, Interactions, Mechanism of Action | DrugBank Online.” Drugbank.com, DrugBank, 2021, go.drugbank.com/drugs/DB01268. Accessed 10 Mar. 2023.
  • Jaini, Ritika, et al. “Combination of Sunitinib with Anti-Tumor Vaccination Inhibits T Cell Priming and Requires Careful Scheduling to Achieve Productive Immunotherapy.” International Journal of Cancer, vol. 134, no. 7, Oct. 2013, pp. 1695–705, https://doi.org/10.1002/ijc.28488. Accessed 10 Mar. 2023. ‌
  • Rizzo, Mimma, and Camillo Porta. “Sunitinib in the Treatment of Renal Cell Carcinoma: An Update on Recent Evidence.” Therapeutic Advances in Urology, vol. 9, no. 8, June 2017, pp. 195–207,https://doi.org/10.1177/1756287217713902. Accessed 10 Mar. 2023. ‌

FAQ

What therapeutic category is sunitinib?

Sunitinib is a chemotherapeutic drug and receptor tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). Sunitinib is a tiny chemical that inhibits many receptor tyrosine kinases (RTKs).

Is sunitinib used in immunotherapy?

Sunitinib and other protein tyrosine kinase inhibitors have been shown to be successful therapeutics and have the potential to offer long-term and effective immunotherapy when used in conjunction with such techniques.

How is sunitinib used for renal cell carcinoma?

Sunitinib (SU011248) is a small molecule that inhibits several members of the split-kinase domain family of receptor tyrosine kinases (RTKs), including VEGFR types 1 and 2 (FLT1 and FLK1/KDR), platelet-derived growth factor receptors (PDGFR- and PDGFR-), the stem cell factor receptor c-KIT, and the FLT3 and RET kinases.